SMO

SMO Molekülinformation

Englischer Name	Smoothened receptor	Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	5	Target-Alias	SMO，SMOH，Smoothened， Frizzled Class Receptor，Smoothened， Frizzled Family Receptor，Frizzled Family Member 11，Protein Gx，Seven Transmembrane Helix Receptor，Smoothened Homolog (Drosophila)，Smoothened Homolog，FZD11，CRJS，Gx，Smoothened Receptor，Smoothened， Seven Transmembrane Spanning Receptor，Smoothened (Drosophila) Homolog
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Smoothened receptor
Target-Alias	SMO，SMOH，Smoothened， Frizzled Class Receptor，Smoothened， Frizzled Family Receptor，Frizzled Family Member 11，Protein Gx，Seven Transmembrane Helix Receptor，Smoothened Homolog (Drosophila)，Smoothened Homolog，FZD11，CRJS，Gx，Smoothened Receptor，Smoothened， Seven Transmembrane Spanning Receptor，Smoothened (Drosophila) Homolog
Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	5
Höchste Forschungs- und Entwicklungsphase	Approved

SMO Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
- (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
SMO-H52D3	Human	HEK293	Human SMO Protein, His,Flag Tag (Detergent)				In den Warenkorb legen
SMO-H52P3	Human	HEK293	Human SMO Full Length Protein (VLP)				In den Warenkorb legen

Gesamtmenge2

SMO Molekülhintergrund

The protein encoded by this gene is a G protein-coupled receptor that interacts with the patched protein, a receptor for hedgehog proteins. The encoded protein tranduces signals to other proteins after activation by a hedgehog protein/patched protein complex.

SMO Molekülalias

SMO,smoothened, frizzled class receptor,CRJS, FZD11, Gx, PHLS, SMOH

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Patidegib	SGT-610; BBP-009; FIN-5; IPI-926	Phase 3 Clinical	Infinity Pharmaceuticals Inc	Adenocarcinoma; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Chondrosarcoma; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Primary Myelofibrosis	Details
Taladegib	ENV-IPF-101; ENV-ONC-101; LY-2940680; ENV-101; RXDX-109	Phase 2 Clinical	Eli Lilly And Company	Breast Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Medulloblastoma; Neoplasm Metastasis; Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Solid tumours	Details
GT-1708F	GT-1708F; GT-1708; GT1708F	Phase 2 Clinical	Suzhou Koshine Biomedica Inc	Hematologic Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours	Details
Cipromedegib	SHR-1539	Phase 1 Clinical	Jiangsu Hengrui Medicine Co Ltd	Solid tumours	Details
ZSP-1602	ZSP-1602	Phase 1 Clinical	Guangdong Zhongsheng Pharmaceutical Co Ltd	Carcinoma; Carcinoma, Basal Cell; Carcinoma, Neuroendocrine; Esophageal Neoplasms; Glioblastoma; Glioma; Medulloblastoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Sonidegib Diphosphate	LDE-225; NVP-LDE-225	Approved	Novartis Pharma Ag	Odomzo, 奥昔朵	United States	Carcinoma, Basal Cell	Sun Pharmaceutical Industries Ltd	2015-07-24	Astrocytoma; Basal Cell Nevus Syndrome; Blood Coagulation Disorders; Blood Platelet Disorders; Bone Marrow Diseases; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Hemorrhagic Disorders; Hepatic Insufficiency; Hepatoblastoma; HR-positive breast cancer; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Liver Cirrhosis; Liver Dysfunction; Lung Neoplasms; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neuroblastoma; Ovarian Neoplasms; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Prostatic Neoplasms; Rhabdomyosarcoma; Skin Neoplasms; Solid tumours; Stomach Neoplasms; Thrombocythemia, Essential; Thrombocytosis;	Details
Glasdegib	PF-04; PF-4449913; PF-04449913	Approved	Pfizer Inc	Daurismo	United States	Leukemia, Myeloid, Acute	Pfizer Inc	2018-11-21	Fasciitis; Graft vs Host Disease; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Primary Myelofibrosis; Renal Insufficiency; Solid tumours	Details
Vismodegib	R-3616; RG-3616; GDC-0449	Approved	F. Hoffmann-La Roche Ltd, Genentech Inc	Erivedge	United States	Carcinoma, Basal Cell	Genentech Inc	2012-01-30	Adenocarcinoma; Basal Cell Nevus Syndrome; Brain Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Central Nervous System Lymphoma; Chondrosarcoma; Chondrosarcoma, Clear Cell; Chondrosarcoma, Extraskeletal Myxoid; Chondrosarcoma, Mesenchymal; Colorectal Neoplasms; Dermatofibrosarcoma; Desmoplastic Small Round Cell Tumor; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Graft vs Host Disease; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Hematologic Neoplasms; Idiopathic Pulmonary Fibrosis; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Medulloblastoma; Mesenchymoma; Multiple Myeloma; Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Neurofibrosarcoma; Odontogenic Cyst, Calcifying; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Alveolar Soft Part	Details